| ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Home | | | Search | | | Browse | | | Resources | | | Help | | | What's New | | | About | |
Rheopheresis Blood Filtration Study for the Treatment of Dry Age-Related Macular Degeneration (AMD)
This study is currently recruiting patients.
| Sponsored by: | Vascular Sciences Corporation |
|---|---|
| Information provided by: | Vascular Sciences Corporation |
Purpose
AMD is a progressive disease of the retina which is nourished by a network of tiny blood vessels. There is evidence to suggest that the flow of nutrients to the retina is impaired in patients with AMD. Rheopheresis blood filtration uses blood filters that deplete excesses of large proteins, fats and other substances from the blood, improving blood flow to the macula, potentially improving vision.
| Condition | Treatment or Intervention | Phase |
|---|---|---|
| Macular Degeneration |
Device: Rheopheresis blood filtration |
Phase III |
MedlinePlus related topics: Macular Degeneration
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Single Group Assignment, Safety/Efficacy Study
Expected Total Enrollment: 180
Study start: August 1999;
Study completion: June 2006
Last follow-up: February 2006;
Data entry closure: June 2006
Eligibility
Ages Eligible for Study: 50 Years - 85 Years, Genders Eligible for Study: Both
Accepts Healthy Volunteers
Criteria
Location
and Contact
Information
More Information
Publications
 | ||||||||||||||
| U.S. National Library of Medicine, Contact NLM Customer Service | ||||||||||||||
| National Institutes of Health, Department of Health & Human Services | ||||||||||||||
| Copyright, Privacy, Accessibility, Freedom of Information Act | ||||||||||||||